Amgen (NASDAQ:AMGN - Get Free Report) had its target price reduced by UBS Group from $314.00 to $284.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a "neutral" rating on the medical research company's stock. UBS Group's target price points to a potential upside of 8.09% from the company's current price.
Several other equities research analysts also recently issued reports on AMGN. Royal Bank of Canada reissued an "outperform" rating and set a $329.00 price objective on shares of Amgen in a research report on Wednesday, April 3rd. Oppenheimer reissued an "outperform" rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. StockNews.com downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research report on Thursday, March 28th. Daiwa Capital Markets raised shares of Amgen from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. Finally, The Goldman Sachs Group raised their target price on shares of Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a research report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $296.95.
Read Our Latest Analysis on Amgen
Amgen Trading Down 0.5 %
NASDAQ:AMGN traded down $1.32 during trading hours on Wednesday, hitting $262.75. The stock had a trading volume of 2,082,465 shares, compared to its average volume of 2,851,966. Amgen has a one year low of $211.71 and a one year high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market cap of $140.81 billion, a price-to-earnings ratio of 21.04, a P/E/G ratio of 2.47 and a beta of 0.58. The business's 50 day moving average is $277.34 and its 200-day moving average is $281.24.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the prior year, the firm earned $4.09 earnings per share. The business's quarterly revenue was up 19.8% on a year-over-year basis. Sell-side analysts anticipate that Amgen will post 19.46 EPS for the current fiscal year.
Institutional Trading of Amgen
A number of hedge funds have recently modified their holdings of AMGN. OFI Invest Asset Management acquired a new stake in shares of Amgen during the 3rd quarter worth about $26,000. Briaud Financial Planning Inc acquired a new stake in Amgen in the 3rd quarter worth about $26,000. Strategic Investment Solutions Inc. IL acquired a new stake in Amgen in the 1st quarter worth about $28,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen in the 4th quarter worth about $29,000. Finally, United Community Bank acquired a new stake in Amgen in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 76.50% of the company's stock.
About Amgen
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
